<DOC>
	<DOCNO>NCT00001026</DOCNO>
	<brief_summary>Primary : To determine whether combination vaccination , i.e. , prim vaccinia recombinant-containing HIV envelope ( HIVAC-1e ) follow boost recombinant subunit envelope protein ( gp160 gp120 ) , provide enhanced immunogenicity compare subunit vaccination individual recombinant envelope proteins . To compare relative immunogenicity panel HIV envelope subunit vaccine administer booster follow recombinant HIV-vaccinia priming . To evaluate relative immunogenicity one versus two dos recombinant HIV-vaccinia prior subunit protein boost . Secondary : To examine safety administer individual subunit vaccine combination HIV envelope vaccinia recombinant , extend population protein administer . Previous study suggest prim HIV-vaccinia recombinant follow boost subunit envelope proteins offer promise strategy date safe immunogenic vaccine human . This study examine combination vaccine approach define optimal prime-boost strategy .</brief_summary>
	<brief_title>A Phase I , Multicenter , Randomized Trial Evaluate Safety Immunogenicity Recombinant Vaccinia-HIV Envelope Vaccine ( HIVAC-1e ) Combination With Panel Subunit Recombinant HIV Envelope Vaccines Vaccinia-Naive Individuals</brief_title>
	<detailed_description>Previous study suggest prim HIV-vaccinia recombinant follow boost subunit envelope proteins offer promise strategy date safe immunogenic vaccine human . This study examine combination vaccine approach define optimal prime-boost strategy . Healthy volunteer randomize one eight group . All patient receive initial immunization HIVAC-1e , follow two boost month 8 12 rgp120/HIV-1SF2 ( BIOCINE ) , rgp120/HIV-1IIIB ( Genentech ) , rgp120/HIV-1MN ( Genentech ) , gp160 MN ( Immuno-AG ) . Additionally , half patient subunit vaccine group receive repriming HIVAC-1e month 4 . Subjects follow 18 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Subjects must : Normal history physical exam . Negative HIV screen ELISA , Western blot , p24 antigen ( PBMC HIV culture HIVspecific PCR substitute Western blot p24 antigen ) . No history smallpox ( vaccinia ) vaccination . Normal urinalysis . Absolute CD4 count = &gt; 500 cells/mm3 . Exclusion Criteria Coexisting Condition : Subjects follow condition exclude : Hepatitis B surface antigenemia . Medical psychiatric condition precludes compliance protocol . Subjects follow prior condition exclude : History immunodeficiency chronic illness . Eczema within past year . Prior Medication : Excluded : Prior experimental HIV vaccine . Prior smallpox vaccine . Immunoglobulin administration within 2 month prior enrollment . Any experimental agent within 2 month prior enrollment . History use immunosuppressive medication . Prior Treatment : Excluded : Blood blood product transfusion within past 6 month . 1 . Current high risk HIV transmission ( person previously high risk HIV transmission enrol provided negative HIV screen highrisk behavior practice within last 6 month ) . Household contact anyone pregnant , eczema , less 12 month age , immunodeficiency disease use immunosuppressive medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Vaccinia Virus</keyword>
	<keyword>Viral Vaccines</keyword>
	<keyword>HIV Envelope Protein gp160</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>